Resistance to imatinib in the treatment of chronic myelogenous leukemia (CML) may occur due to amplification of the Bcr-Abl gene, but more frequently by point mutations causing substitutions of critical amino-acid residues in the Abl kinase domain. 1 More than 40 different mutations have been described so far. 2 They confer resistance due to amino-acid substitutions, which impair drug binding without influencing ATP binding. 3 Here, we describe the clinical and molecular features of two imatinib-resistant CML patients ('A' and 'B') bearing the L248V mutation in the Bcr-Abl kinase domain. Interestingly, this Molecular analysis of clinical response. Using real-time-PCR at various time points before and after transplantation, the level of residual bcr/abl compared to total Abl RNA was measured in peripheral blood samples. Values under the dashed horizontal line in the respective graph were below the routinely achievable limit of detection of real-time-PCR (10
À4
). Time points of the infusion of CTLs are depicted by black arrows. The respective cell dose/kg is provided.
Letters to the Editor mutation, a C to G transversion at position 1106, activates a cryptic splice donor sequence. Awareness of this deleted isoform seems essential to secure correct diagnosis of the L248V mutation, particularly when using sequencing, as mixed sequences will occur.
Mr A (67 years) showed an initial major cytogenetic response to imatinib in early chronic phase (CP), but subsequently developed disease progression, in spite of augmented doses of imatinib, to 97% Ph-positive metaphases and a 22% Bcr-Abl/ Abl ratio by real-time quantitative reverse transcriptase PCR (qRT-PCR) after 15 months of treatment. 4 Mrs B (75 years) also started imatinib in CP, but transformed to accelerated phase after 17 months of treatment, with a Bcr-Abl/Abl ratio of 17%. When subjected to mutational analysis using a sensitive PCR screen for 11 predefined mutations associated with imatinib resistance, 5 the existence of a dominant L248V Bcr-Abl clone was verified in both subjects with L248V/Abl ratios of 20% (A) and 17% (B), respectively. Additional sequencing of the Abl kinase domain 6 confirmed dominance of the mutant G allele (position 1106). However, as shown in Figure 1a , sequence analysis suggested the presence of mixed templates indicating heterogeneity. Additional cDNA cloning using a Topo pCR 2.1 vector according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA) and sequencing of single clones confirmed the presence of two Bcr-Abl transcripts: one containing a C-G transversion at position 1106 associated with the L248V substitution (panel b) and another shorter, obviously deleted variant (panel c). As illustrated in panel d, a web-based Figure 1 Abl kinase domain sequence abnormalities identified in association with clinical imatinib resistance due to the L248V mutation. In two imatinib-resistant subjects, we detected a C-G transition at position 1106. As illustrated in (a) (actual sequence subject A) the mutated G allele existed in mixed clonality with the wild-type C allele (predominantly mutant). We noticed that an initial high-quality reading was followed by a mixed sequence downstream of the mutated nucleotide. Additional cloning of a gene fragment encoding the kinase domain followed by sequencing of individual clones confirmed the suspected existence of two variants: the normal kinase domain sequence containing the described point mutation (b) and a deleted variant (c). The deletion encompasses 81 base pairs from nucleotide 1106 to the last nucleotide of exon 4 (nucleotide 1186). Apparently, the mutation activates a cryptic 5 0 donor splice site. To estimate the probability of splicing, we conducted an automated splicing mutational analysis 7 (d). A 10-fold increase in information content in this analysis suggests that the C-G transition actually initiates splicing. (e) The extent of the deletion, stretching 27 amino acids from the N-terminal lobe of the kinase domain including the entire P-loop and two adjacent beta-strands, is shown in this ribbon model of mouse c-abl made using ICM Browser (www.molsoft.com) and available structural data (1IEP, Protein Data Bank, www.iscb.pdb.org; Schindler et al. Letters to the Editor automated splicing mutation analysis based on information theory 7 (https://splice.cmh.edu) suggested an activation of a cryptic 5 0 donor splice site within exon 4, yielding a splice variant with a deletion of 81 nucleotides from nucleotide position 1106 to the very end of exon 4 (position 1186) (panels c and d). This results in a deletion of 27 amino acids (position 248-274) of the N-terminal lobe of the kinase domain, including the entire P-loop region and two antiparallel beta-strands (Figure 1e) . Thus, the ATP binding pocket is lost, making it highly unlikely that the resultant Bcr-Abl protein encoded by the (D248-274)-splice variant will possess any kinase activity. It is possible that this isoform can act as a dominant-negative mutant versus Bcr-Abl and the full-length isoform of the L248V mutant.
Both patients expressed mutant Bcr-Abl alleles with the normal and variant (D248-274)-splice isoforms. To further investigate the frequency of the (D248-274)-splice isoform, we sequenced 10 individual cDNA clones from each subject. In A, three clones represented this isoform and in B only one out of 10. For both subjects, all the clones representing the normal isoform contained the mutated G at position 1106 (data not shown).
Furthermore, the disease status of Mr A was followed sequentially during treatment with dasatinib with quantitative Taqman-based PCR assays for Bcr-Abl, 4 the L248V mutant and a novel assay for the analysis of the (D248-274)-splice isoform, using primer combinations specifically amplifying the L248V variant 5 and the L248V deletion variant (forward primer: 5 0 -GGTGTGTCCCCCAACTACGA-3 0 ; probe: 5 0 -FAM-AAGTGGGA GATGGAACGCACGGAC-TAMRA-3 0 ; reverse primer: 5 0 -ATGG TGTCCTCCTTGTG-3 0 ; the PCR assays were run using conditions described by Gruber et al. 5 ). Figure 2 illustrates the response kinetics to dasatinib treatment. Thus, the mRNA amounts of total Bcr-Abl, as well as of both splice isoforms (the L248V and (D248-274)-splice variants), decreased significantly by 42-3 logs to non-detectable levels, indicating effective inhibition by the drug. In parallel, metaphase analyses confirmed a complete cytogenetic response. The amount of mRNA of the (D248-274)-splice isoform paralleled the curve pattern of full-length L248V.
It may be speculated whether the discovered spliced variant is uncommon. In both our cases with detected L248V mutation, we observed the deletion variant by routine sequencing. It seems likely that the L248V Bcr-Abl variant is associated with alternative splicing products. This may previously have been overlooked. The alternative splicing phenomenon makes the detection of the L248V mutated Bcr-Abl variant more difficult by sequencing procedures. Mixed sequences may be interpreted as reduced-quality readings and therefore result in withdrawal from the diagnostic procedure. Consequently, the incidence of the L248V mutation in imatinib-resistant patients may be underestimated owing to this splicing event and the resulting sequence overlays.
In conclusion, we report that the C-G mutation at position 1106, resulting in the imatinib-resistant Bcr-Abl variant L248V, can additionally induce the alternative splicing of a shorter variant by introducing a donor splice site within Abl exon 4. We predict that the splice variant is without tyrosine kinase activity. Possibly, it may even function in a dominant-negative manner. Furthermore, we show by selective, quantitative follow-up of the mRNA variants in an imatinib-resistant patient that dasatinib treatment can profoundly decrease the full-length L248V as well as the (D248-274)-splice isoform. Detection of the (D248-274)-splice isoform may pose a diagnostic problem when PCR product sequencing is used for detection of resistance mutations of Bcr-Abl. Assessment of tumor burden during treatment with dasatinib. The amounts of mRNA transcripts for total Bcr-Abl, the L248V and L248V deletion variant were followed quantitatively by qRT-PCR upon dasatinib treatment ('Mr A'). Results were expressed as a ratio percent relative to total Abl copy number (Bcr-Abl and Abl). After treatment for 6 months, the dominating imatinib-resistant L248V Bcr-Abl clone was no longer detectable. In parallel, the deleted variant (alternatively spliced transcript) decreased following dasatinib treatment. The stippled, horizontal line denotes the detection limit and & denotes samples with undetectable targets. In the majority of patients the distinction between myelodysplastic syndromes (MDSs) and chronic myeloprololiferative disorders is made relatively easily by assessment of clinical, laboratory and morphological characteristics of the peripheral blood and bone marrow. However, the existence of uni-or mulitlineage dysplasia and hyperplastic myelopoiesis in the same patient is well recognized and classified by the World Health Organization (WHO) as myelodysplastic/myeloproliferative disease, unclassifiable. 1 Within this group is a provisional entry referred to as refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (platelets 4600 Â 10 9 /l) (RARS-T). 1 The relationship between dysplasia and the proliferation is not entirely clear, but the recent discovery of a single somatic point mutation in the pseudokinase domain of the Janus kinase 2 (JAK2) resulting in a codon change V617F represents a potential major breakthrough in the pathogenesis of myeloproliferation. Mutation at this site results in the constitutive activation of the JAK2 kinase and thus the activation of the JAK2 pathway. This mutation is present in the majority (495%) of patients with polycythaemia vera and approximately half of those with primary thrombocythaemia and myelofibrosis 2 and others. We have recently reported a high incidence (61%) of the V617F mutation in patients with Budd Chiari syndrome who lack features of a frank proliferative disorder. 3 The prevalence of JAK2 V617F mutation in atypical MPDs or MDS is generally low. 4 Identification of this mutation in MDS identifies a subset of patients with a prominent proliferative component. 5 The lack of a precise molecular definition for most cases of MDS, with the exception of 5qÀ syndrome, testifies to the heterogenous nature of this disorder.
We analysed 70 patients from two European centres with a diagnosis of MDS with ringed sideroblasts of X15% (as defined by the WHO classification), for the presence of the JAK2 V617F mutation. A summary of patient's characteristics is shown in Table 1 . DNA samples for analysis were obtained from archived bone marrow aspirate slides or from fresh peripheral blood taken from patients presenting to our centres. Ethical approval was obtained before the study commenced.
Genomic DNA was prepared using standard methods (Qiagen, House, Crawley, West Sussex, UK). A modified allele-specific PCR (AS-PCR) was used to screen DNA samples.
